FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin

Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers and not where in the body the tumor originated.

Read More

Scientist↔Survivor Program Participants Spend a Memorable Day on Capitol Hill

US Capitol Building

May is National Cancer Research Month, and for the past 10 years, leaders and members from the American Association for Cancer Research (AACR), the Association of American Cancer Institutes (AACI), and the American Society of Clinical Oncology (ASCO) have converged on Capitol Hill during May to share how cancer research is saving lives and transforming patient care.

Read More

Advancing Translational Cancer Medicine in Latin America

In recent years, the American Association for Cancer Research (AACR) has expanded its efforts to catalyze advances in cancer research globally and support its members residing in 107 countries in addition to the United States. One important initiative this year was the landmark conference held May 4-6, in São Paulo, Brazil—the AACR International Conference on Translational Cancer Medicine.

Read More

Do Genomic Approaches to Selecting Cancer Treatment Yield Better Patient Outcomes Than Traditional Approaches?

A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput genomic analysis in identifying targeted therapies and delivering better outcomes for cancer patients, and adds important evidence to argue in favor of such an approach. The jury, nevertheless, is still out.

Read More

FDA Approves Fourth Immune Checkpoint Inhibitor for Bladder Cancer

This time last year there were no immune checkpoint inhibitors approved by the U.S. Food and Drug Administration (FDA) for treating the most common form of bladder cancer—urothelial carcinoma. The approval of avelumab (Bavencio) earlier this week means there are now four of these revolutionary immunotherapeutics in the armamentarium.

Read More

FDA Approves Fourth ALK Inhibitor for Lung Cancer

Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the molecularly targeted therapeutic brigatinib (Alunbrig) for treating certain patients with metastatic non–small cell lung cancer (NSCLC).

Read More

New Immune Checkpoint Inhibitor Approved for Bladder Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) announced that it had approved a new immune checkpoint inhibitor, durvalumab (Imfinzi), for the treatment of certain patients with the most common form of bladder cancer—urothelial carcinoma.

Read More